Research programme: metabolic disorder therapeutics - Synlogic/Ginkgo Bioworks
Latest Information Update: 28 Oct 2025
At a glance
- Originator Ginkgo Bioworks; Synlogic
- Developer Synlogic
- Class Antigouts; Bacteria
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gout; Hyperuricaemia
- No development reported Metabolic disorders